Novo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall 5%
CNBC
Read Full Article at CNBC →Ad Slot — In-Article (728x90)
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
This is a summary. For the full story, read the original article at CNBC.
Original source: CNBC